GlassScriptPhysician profile
Lesley N Bevan
NPI 1154513307
$2,247.00
in general payments reported to CMS, 2019-2025
27 companies · $346 in 2025
The $346 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $119 · 2021: $143 · 2022: $151 · 2023: $805 · 2024: $283 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.96 |
| Education | $208.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $442.13 | 2023-2024 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $363.15 | 2019-2025 | Acessa Provu System, Coolseal Generator, Fetal Fibronectin Enzyme Immunoassay |
| Bayer Healthcare Pharmaceuticals INC. | $219.87 | 2020-2025 | |
| Pfizer INC. | $153.94 | 2019-2023 | |
| Exeltis, USA INC. | $135.68 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $116.16 | 2022-2025 | |
| Abbvie INC. | $102.86 | 2019-2022 | |
| Therapeuticsmd, INC. | $79.87 | 2019-2021 | |
| Coopersurgical, INC. | $77.68 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Covidien LP | $59.43 | 2019-2020 | |
| Davol INC. | $51.49 | 2024 | Arista Ah Flexitip |
| Merck Sharp & Dohme LLC | $49.69 | 2019-2024 | Gardasil 9, Gardasil |
| Si-Bone, INC. | $46.35 | 2019 | |
| Organon LLC | $43.24 | 2024-2025 | Nexplanon |
| Ethicon US, LLC | $42.38 | 2019-2024 | Stratafix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $42.25 | 2019 | |
| Sage Therapeutics, LLC | $36.25 | 2024-2025 | Zurzuvae |
| Becton, Dickinson and Company | $35.64 | 2019 | |
| Sumitomo Pharma America, INC. | $24.95 | 2023 | Myfembree |
| C. R. Bard, INC. & Subsidiaries | $20.24 | 2022 | |
| Alydia Health | $16.22 | 2021 | |
| Daiichi Sankyo INC. | $16.21 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.68 | 2019 | |
| Medicem INC. | $15.50 | 2023 | |
| Vertical Pharmaceuticals, LLC | $15.18 | 2019 | |
| Lupin INC. | $13.66 | 2019 | |
| Allergan, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Bevan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.